Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.

Cristina BezzioAlessandro ArmuzziFederica FurfaroSandro ArdizzoneMonica MillaSonia CarparelliAmbrogio OrlandoFlavio Andrea CaprioliFabiana CastiglioneChiara ViganòDavide Giuseppe RibaldoneFabiana ZingoneRita MonterubbianesiNicola Imperatore Stefano FestaMarco DapernoLudovica ScucchiAntonio FerronatoLuca PastorelliPaola BalestrieriChiara RicciMaria CappelloCarla FeliceGionata FiorinoSimone Saibeninull null

Published in: Alimentary pharmacology & therapeutics (2021)

The course of COVID-19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID-19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID-19 re-vaccination or for therapies for SARS-CoV-2 infection.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
ulcerative colitis
human health
emergency department
risk assessment
skeletal muscle
adipose tissue
climate change
insulin resistance
glycemic control